Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Solid Tumors

Terminated

1

Start Date 10/01/2011

Age of Trial (yrs) 13.5

Gleevec-resistant

PI3K/mTOR inhibitor + MEK inhibitor + TOPO-1 inhibitor

Block related tumor signal paths

GIST not specified. GIST patient enrollment unknown.

B1271002

Pfizer

Pfizer CT.gov Call Center 1-800-718-1021 Pfizer Oncology Clinical Trial Information Service 1-877-369-9753 PfizerCancerTrials@emergingmed.com

Oral Intravenous

Purpose: After the second protocol amendment two study arms are evaluated in this clinical protocol: PD-0325901 (MEK inhibitor) plus PF-05212384 (PI3K/mTOR inhibitor) and PF-05212384 plus irinotecan. The study will assess safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer. Once the maximum tolerated doses are identified, further assessment of these combinations will be done in patients with previously treated metastatic colorectal cancer or pancreatic cancer for the PF-05212384 plus irinotecan arm and in patients with KRAS mutated colorectal cancer for the combination of PF-05212384 plus PD-0325901